Evotec Completes Acquisition of DeveloGen
(Thomson Reuters ONE) -
Evotec AG / Evotec Completes Acquisition of DeveloGen processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Hamburg, Germany - 2 September 2010: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced the Closing of the agreement to acquire DeveloGen as
announced in detail on 14 July 2010.
Following the successful fulfilment of various Closing conditions, the sellers
of 99.3% of the shares in DeveloGen AG today transferred their shares to Evotec
AG. Evotec AG issues 6,750,014 new Evotec Shares from its authorized capital as
part consideration for the transaction. Following the registration of these
shares at the trade register, Evotec's issued share capital will increase to
?115,588,729.
The transaction adds two complementary alliances - one with Boehringer Ingelheim
and one with Andromeda (Teva) - to Evotec's portfolio of core assets. In
addition, it augments and complements Evotec's high-end drug discovery platform
and capability with DeveloGen's target discovery, validation and in vivo/in
vitro pharmacology expertise and adds core disease biology know-how in metabolic
diseases and endocrine disorders. These skills further enhance Evotec's ability
to deliver high quality, innovative solutions to its partners on a global scale.
Contact: Dr Werner Lanthaler, Chief Executive Officer,
Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler(at)evotec.com
Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. Such forward-looking statements include, but are not limited to,
statements about our 2010 financial outlook and our expected financial results
in future quarters, our revised revenue guidance for 2010 and expected revenue
growth, our ability to deliver on our liquidity guidance, our belief that we are
on course to sustainable profitability latest in 2012, our expectations and
assumptions concerning regulatory, clinical and business strategies, the
progress of our clinical development programmes and timing of the commencement
and results of our clinical trials, strategic collaborations and management's
plans, objectives and strategies. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties, many of
which are beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other things: risks that
product candidates may fail in the clinic or may not be successfully marketed or
manufactured; the risk that we will not achieve the anticipated benefits of our
collaborations, partnerships and acquisitions in the timeframes expected, or at
all; risks relating to our ability to advance the development of product
candidates currently in the pipeline or in clinical trials; our inability to
further identify, develop and achieve commercial success for new products and
technologies; the risk that competing products may be more successful; our
inability to interest potential partners in our technologies and products; our
inability to achieve commercial success for our products and technologies; our
inability to protect our intellectual property and the cost of enforcing or
defending our intellectual property rights; our failure to comply with
regulations relating to our products and product candidates, including FDA
requirements; the risk that the FDA may interpret the results of our studies
differently than we have; the risk that clinical trials may not result in
marketable products; the risk that we may be unable to successfully secure
regulatory approval of and market our drug candidates; and risks of new,
changing and competitive technologies and regulations in the U.S. and
internationally.
The list of risks above is not exhaustive. Our most recent Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other documents
filed with, or furnished to the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.
[HUG#1442123]
--- End of Message ---
Evotec AG
Schnackenburgallee 114 Hamburg Germany
WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Pdf of Press Release:
http://hugin.info/131215/R/1442123/386385.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Evotec AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 02.09.2010 - 07:32 Uhr
Sprache: Deutsch
News-ID 40983
Anzahl Zeichen: 0
contact information:
Town:
Hamburg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec Completes Acquisition of DeveloGen"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
